Choose language

en
  • de

  • en

  • es

  • fr

  • it

  • pl

  • pt

  • ru

  • uk

English
  • Deutsch

  • English

  • Español

  • Français

  • Italiano

  • Polski

  • Português

  • Русский

  • Українська

How do you prefer to top up your account?

* We don't charge any commission for making deposits into your account

Shares Sanofi

17.96%
Growth potential
85.32
Price per share
EUR
3.49%
Dividend income
Sanofi sold by lots comprising 1 pc.
Enter the number of securities
Order price:
Brokerage commission:
Transfer commission:
EMPOWERING LIFE
Why invest in Sanofi?
  • World's number five in prescribed drug sales
  • Forms a part of Euro Stoxx 50
  • World's largest vaccine manufacturer
  • €6,022M invested into R&D in 2019


1d
1w
1mo
6mths
All the time
Recommendations of the largest investment banks
Deutsche Bank AG
Sell
70 €
02.03.2021
Goldman Sachs Group Inc.
Buy
106 €
15.02.2021
JP Morgan Chase & Co.
Buy
93 €
12.02.2021
UBS AG
Buy
101 €
10.02.2021
Financial indicators
Capitalization
37.75B €
P / E
7.97
Profit
N/A €
Net profit
40.94B €

Sanofi SA is a multinational pharma company headquartered in Paris, France. Since 2013, this is the world's fifth company by prescribed drug sales. Founded back in 1973, the company was re-structured and re-branded as Sanofi-Aventis in 2004, after the merger of Aventis and Sanofi-Synthélabo, each of both being a result of previous mergers. In May 2011, the company was renamed to Sanofi. The company works in the following fields: cardiovascular system, central nervous system, diabetes, internal medicine, oncology, thrombosis, and vaccines.

Sanofi concluded a few successful acquisitions, the largest being Zentiva, Shantha Biotechnics, Chattem, Medley Pharmaceuticals Ltd., Genzyme, Globalpharma, and Bioverativ.

In Q1 2020, Sanofi's net profit rose by 47% to reach €1.68B, compared to €1.14B in Q1 2019. The earnings soared by 6.90% to €8.973B, or 6.60% currency rate adjusted. The boost occurred thanks to Dupixent, a drug used for eczema and asthma treatment. Dupixent sales skyrocketed by 129.80% to reach €776M.

Meanwhile, the earnings per share soared by 15.60% (no currency rate adjustment) and is now €1.63. Sanofi is still expecting the EPS to rise by 5% more by the end of 2020. Finally, the company's market cap increased by 14.60% over the last month, to reach €111.50B.

Receive ideas for profitable investments - faster than the market

We will be sending you a letter once a week with the most relevant information

Congratulations!

Now you will always be aware of which stocks are more profitable to invest in